Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly and Company has reported a new study, where 60mg of Cymbalta (duloxetine HCl) taken once daily reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) average pain rating. The data were presented at the annual meeting of the American Academy of Pain Medicine (AAPM) in San Antonio, Texas.
Subscribe to our email newsletter
A total of 401 patients participated in the 12-week, double-blind, placebo-controlled study, designed to assess the efficacy of duloxetine 60mg once daily on the reduction of pain severity in patients with chronic low back pain.
In the study, duloxetine-treated patients experienced a greater improvement on BPI average pain scale, compared to placebo, in chronic low back pain (p<0.005).
Adults (N=401) with non-neuropathic chronic low back pain and pain intensity of 4 on the 11-point BPI average pain scale, were treated with either duloxetine 60mg once daily (N=198) or placebo (N=203) for 12 weeks in this randomized, double-blind trial. The primary measure was BPI average pain.
Cymbalta is approved to treat major depressive disorder and generalized anxiety disorder, and to manage diabetic peripheral neuropathic pain and fibromyalgia.